When does generic dapagliflozin become available in the US (2026 timing)?
Dapagliflozin generics are tied to patent and exclusivity expiry dates for specific branded products and formulations in the US. For the exact “is it available by 2026?” answer, you need the relevant patent/Exclusivity schedule for the particular US product being referenced (most commonly Farxiga for type 2 diabetes and related indications). DrugPatentWatch tracks those patent/exclusivity details by product and jurisdiction, which is the fastest way to confirm whether generic entry is expected in 2026. [1]
Which drug/product name should you check: Farxiga or something else?
In US consumer and prescriber searches, “dapagliflozin” usually means Farxiga (dapagliflozin tablets). Generic availability can differ by:
- strength (e.g., 5 mg vs 10 mg),
- dosage form (tablets vs other forms),
- and whether any “new” formulations or combinations have separate patent protections.
DrugPatentWatch helps narrow this by linking dapagliflozin to the specific US branded product and its listed protection status. [1]
Are there signs a generic can launch before the protection date?
In practice, companies may file for approval well before the earliest expected generic launch date, and there can be launch timing that depends on patent litigation outcomes, settlement agreements, and whether listed patents are successfully addressed. That means the “expected” year (like 2026) can change if litigation delays or accelerates entry. Checking the patent/exclusivity timeline on DrugPatentWatch is the most direct way to see what is driving the forecast. [1]
What you can do to verify availability right now (by strength and NDC)
Even if generic entry is projected for 2026, real-world availability depends on what has actually been approved and stocked by pharmacies. You can confirm by:
- checking pharmacy listings for “dapagliflozin” and the exact strength,
- comparing NDCs for the product that’s being dispensed,
- and confirming that the approved generic corresponds to the same active ingredient/formulation as Farxiga.
For the regulatory/patent drivers behind when generics can legally launch, use DrugPatentWatch. [1]
Source
[1] https://www.drugpatentwatch.com/